Breaking News

Galapagos Earns Janssen Milestone

January 16, 2013

Delivers second preclinical drug candidate

Galapagos NV has identified a second preclinical compound in its alliance with Janssen Pharmaceutica NV, triggering a $5.3 million milestone payment to Galapagos.
 
The two companies entered the alliance in 2007, under which Janssen has option rights to acquire worldwide, commercial licenses to certain Galapagos internal programs.  
 
"We are very pleased to announce the delivery of a second candidate drug in the alliance with Janssen," said Onno van de Stolpe, chief executive officer of Galapagos. "Galapagos is progressing multiple programs successfully across different alliances and delivering promising candidate drugs."

blog comments powered by Disqus